Cargando…

Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma

BACKGROUND: Patients with advanced gallbladder and biliary tract carcinoma face a dismal prognosis, as no effective palliative chemotherapy exists. The antitumor effect of gemcitabine is schedule-dependent rather than dose-dependent. We evaluated the activity of a prolonged infusion of gemcitabine i...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Delius, Stefan, Lersch, Christian, Schulte-Frohlinde, Ewert, Mayr, Martina, Schmid, Roland M, Eckel, Florian
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1180427/ https://www.ncbi.nlm.nih.gov/pubmed/15949047 http://dx.doi.org/10.1186/1471-2407-5-61

Ejemplares similares

Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract
por: Hsu, C, et al.
Publicado: (2004)

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
por: Pignochino, Ymera, et al.
Publicado: (2010)

Liver function assessment using indocyanine green plasma disappearance rate in a young male with icteric leptospirosis: a case report
por: Kunikowska, Alicja J., et al.
Publicado: (2019)

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials
por: Eckel, F, et al.
Publicado: (2007)

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
por: Hezel, A F, et al.
Publicado: (2014)

Effect of midkine on gemcitabine resistance in biliary tract cancer
por: Lu, Yongliang, et al.
Publicado: (2018)

Helicobacter species in cancers of the gallbladder and extrahepatic biliary tract
por: de Martel, C, et al.
Publicado: (2009)

Gallbladder Agenesis without Additional Biliary Tracts Abnormality
por: Meshkati Yazd, Seyed Mostafa, et al.
Publicado: (2022)

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
por: Harder, J, et al.
Publicado: (2006)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Pathology of the pancreas, gallbladder, extrahepatic biliary tract, and ampullary region /
por: Lack, Ernest E.
Publicado: (2003)

A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.
por: Anderson, H., et al.
Publicado: (1996)

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
por: Clamp, A R, et al.
Publicado: (2003)

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
por: André, T, et al.
Publicado: (2008)

BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer
por: Nakashima, Shinsuke, et al.
Publicado: (2015)

Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer
por: Zhao, Qing, et al.
Publicado: (2015)

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
por: Park, Joon Oh, et al.
Publicado: (2015)

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
por: Inoue, Hiroto, et al.
Publicado: (2021)

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994)

SIUMB recommendations on the use of ultrasound in neoplastic lesions of the gallbladder and extrahepatic biliary tract
por: de Sio, Ilario, et al.
Publicado: (2023)

Impact of the COVID-19 Pandemic on the Management of Gallbladder, Biliary Tract, and Pancreatic Diseases
por: Ilyas Khan, Amnah, et al.
Publicado: (2023)

Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone
por: Murata, Akihiro, et al.
Publicado: (2013)

A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan
por: Tsukiyama, Ikuto, et al.
Publicado: (2016)

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
por: Suzuki, Eiichiro, et al.
Publicado: (2013)

Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction
por: Shibata, Takashi, et al.
Publicado: (2016)

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
por: Ikeda, Masafumi, et al.
Publicado: (2017)

Role of Maintenance Gemcitabine in Advanced Carcinoma Gallbladder
por: Sharma, Manish, et al.
Publicado: (2020)

Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973–2007
por: Alberts, Steven R., et al.
Publicado: (2012)

The link between Helicobacter pylori infection and gallbladder and biliary tract diseases: A review
por: Lim, Klay Puay Khim, et al.
Publicado: (2023)

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial
por: Markussen, Alice, et al.
Publicado: (2020)

Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial
por: Lorenzen, S, et al.
Publicado: (2005)

Gemcitabine and S-1 Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer: A Retrospective Study
por: Mita, Kazuhito, et al.
Publicado: (2010)

Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines
por: Sakamoto, Yasunari, et al.
Publicado: (2019)

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers
por: Wu, Chiao-En, et al.
Publicado: (2020)

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Stroke Recovery in Rats after 24‐Hour–Delayed Intramuscular Neurotrophin‐3 Infusion
por: Duricki, Denise A., et al.
Publicado: (2018)

A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer
por: Kollmannsberger, C, et al.
Publicado: (2000)

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)
por: Ioka, Tatsuya, et al.
Publicado: (2022)

Multiseptate gallbladder presenting with biliary colic
por: Hopmann, Peter, et al.
Publicado: (2022)

Retrospective analysis of canine gallbladder contents in biliary sludge and gallbladder mucoceles
por: MIZUTANI, Shinya, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_igbfiadbmm5a935s0t95jmkfbv